A Contemporary Overview of PPARα/γ Dual Agonists for the Management of Diabetic Dyslipidemia

被引:26
作者
Balakumar, Pitchai [1 ]
Mahadevan, Nanjaian [2 ]
Sambathkumar, Ramanathan [1 ]
机构
[1] JKK Nattraja Coll Pharm, Kumarapalayam 638183, Tamil Nadu, India
[2] King Khalid Univ, Coll Pharm, Abha 62529, Saudi Arabia
关键词
PPAR alpha/gamma dual agonists; insulin resistance; diabetic dyslipidemia; adverse effects; cardiovascular events; oedema; PEROXISOME PROLIFERATOR; DOUBLE-BLIND; INSULIN-RESISTANCE; URINARY-BLADDER; MURAGLITAZAR; SAROGLITAZAR; ALEGLITAZAR; ACTIVATION; IMPROVES; SAFETY;
D O I
10.2174/1874467212666190111165015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Diabetes mellitus and concomitant dyslipidemia, being referred to as 'diabetic dyslipidemia', arc the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with insulin resistance, high plasma triglyceride levels, low HDL-cholesterol concentration and elevated small dense LDL-cholesterol particles. Maintaining an optimal glucose and lipid levels in patients afflicted with diabetic dyslipidemia could be a major task that might require a well-planned diet-management system and regular physical activity, or otherwise an intake of combined antidiabetic and antihyperlipidemic medications. Synchronized treatment which efficiently controls insulin resistance-associated diabetes mellitus and co-existing dyslipidemia could indeed be a fascinating therapeutic option in the management of diabetic dyslipidemia. Peroxisome proliferator-activated receptors alpha/gamma (PPAR alpha/gamma) dual agonists are such kind of drugs which possess therapeutic potentials to treat diabetic dyslipidemia. Nevertheless, PPAR alpha/gamma dual agonists like muraglitazar, naveglitazar, tesaglitazar, ragaglitazar and aleglitazar have been reported to have undesirable adverse effects, and their developments have been halted at various stages. On the other hand, a recently introduced PPAR alpha/gamma dual agonist, saroglitazar is an emerging therapeutic agent of glitazar class approved in India for the management of diabetic dyslipidemia, and its treatment has been reported to be generally safe and well tolerated. Conclusion: Some additional and new compounds, at initial and preclinical stages, have been recently reported to possess PPAR alpha/gamma dual agonistic potentials with considerable therapeutic efficacy and reduced adverse profile. This review sheds light on the current status of various PPAR alpha/gamma dual agonists for the management of diabetic dyslipidemia.
引用
收藏
页码:195 / 201
页数:7
相关论文
共 42 条
  • [21] Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus
    Hamren, Bengt
    Oehman, K. Peter
    Svensson, Maria K.
    Karlsson, Mats O.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (09) : 1317 - 1327
  • [22] Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects
    Jani, Rajendra H.
    Kansagra, Kevinkumar
    Jain, Mukul R.
    Patel, Harilal
    [J]. CLINICAL DRUG INVESTIGATION, 2013, 33 (11) : 809 - 816
  • [23] A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)
    Jani, Rajendrakumar H.
    Pai, Vikas
    Jha, Pramod
    Jariwala, Gunjan
    Mukhopadhyay, Satinath
    Bhansali, Anil
    Joshi, Shashank
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2014, 16 (02) : 63 - 71
  • [24] A Newly Identified CG301269 Improves Lipid and Glucose Metabolism Without Body Weight Gain Through Activation of Peroxisome Proliferator-Activated Receptor α and γ
    Jeong, Hyun Woo
    Lee, Joo-Won
    Kim, Woo Sik
    Choe, Sung Sik
    Kim, Kyung-Hee
    Park, Ho Seon
    Shin, Hyun Jung
    Lee, Gha Young
    Shin, Dongkyu
    Lee, Hanjae
    Lee, Jun Hee
    Choi, Eun Bok
    Lee, Hyeon Kyu
    Chung, Heekyoung
    Park, Seung Bum
    Park, Kyong Soo
    Kim, Hyo-Soo
    Ro, Seonggu
    Kim, Jae Bum
    [J]. DIABETES, 2011, 60 (02) : 496 - 506
  • [25] Saroglitazar for the treatment of dyslipidemia in diabetic patients
    Joshi, Shashank R.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (04) : 597 - 606
  • [26] Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice
    Jung, Hoe-Yune
    Kim, Bobae
    Ryu, Hye Guk
    Ji, Yosep
    Park, Soyoung
    Choi, Seung Hee
    Lee, Dohyun
    Lee, In-Kyu
    Kim, Munki
    Lee, You Jeong
    Song, Woojin
    Lee, Young Hee
    Choi, Hyung Jin
    Hyun, Chang-Kee
    Holzapfel, Wilhelm H.
    Kim, Kyong-Tai
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (07) : 1688 - 1701
  • [27] Antidiabetic effect of SN158 through PPARα/γ dual activation in ob/ob mice
    Jung, Yujung
    Cao, Yongkai
    Paudel, Suresh
    Yoon, Goo
    Cheon, Seung Hoon
    Bae, Gyu-Un
    Jin, Li Tai
    Kim, Yong Kee
    Kim, Su-Nam
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2017, 268 : 24 - 30
  • [28] Anti-diabetic effect of amorphastilbol through PPARα/γ dual activation in db/db mice
    Lee, Woojung
    Ham, Jungyeob
    Kwon, Hak Cheol
    Kim, Yong Kee
    Kim, Su-Nam
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2013, 432 (01) : 73 - 79
  • [29] Effect of Aleglitazar on Cardiovascular Outcomes After Acute Coronary Syndrome in Patients With Type 2 Diabetes Mellitus The AleCardio Randomized Clinical Trial
    Lincoff, A. Michael
    Tardif, Jean-Claude
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Ryden, Lars
    Neal, Bruce
    Malmberg, Klas
    Wedel, Hans
    Buse, John B.
    Henry, Robert R.
    Weichert, Arlette
    Cannata, Ruth
    Svensson, Anders
    Volz, Dietmar
    Grobbee, Diederick E.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (15): : 1515 - 1525
  • [30] Urothelial Carcinogenesis in the Urinary Bladder of Rats Treated with Naveglitazar, a γ-dominant PPAR α/γ Agonist: Lack of Evidence for Urolithiasis as an Inciting Event
    Long, Gerald G.
    Reynolds, Vincent L.
    Lopez-Martinez, Alric
    Ryan, Thomas E.
    White, Sandy L.
    Eldridge, Sandra R.
    [J]. TOXICOLOGIC PATHOLOGY, 2008, 36 (02) : 218 - 231